International journal of hematology · 2022
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Funakoshi Yohei, Yakushijin Kimikazu, Ohji Goh, Hojo Wataru, Sakai Hironori, Watanabe Marika, Saeki Miki, Hirakawa Yuri, Sakai Rina, Matsumoto Sakuya, Mizutani Yu, Kitao Akihito, Miyata Yoshiharu, Saito Yasuyuki, Kawamoto Shinichiro, Yamamoto Katsuya, Ito Mitsuhiro, Nishimura Meiko, Imamura Yoshinori, Kiyota Naomi, Matsuoka Hiroshi, Mori Yasuko, Minami Hironobu
Аннотация
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.